Suchergebnisse - "Doebele, Robert C"

PubPharm (202)

1

Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2

enthalten in: Cell chemical biology | 2024

von Liao, Y. | Remsing Rix, L. | Li, X. | +8

2

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling

enthalten in: Molecular cancer therapeutics | 2024

von Chen, N. | Tyler, L. | Le, A. | +9

3

Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression

enthalten in: Thoracic cancer | 2023

von Peters, T. | Chen, N. | Tyler, L. | +3

4

Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing

enthalten in: bioRxiv.org | 2023

von Maynard, A. | McCoach, C. | Rotow, J. | +36

5

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Elkrief, A. | Odintsov, I. | Markov, V. | +16

CommentIn: J Thorac Oncol. 2023 Sep;18(9):1111-1113. - PMID 37599041

6

A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes

enthalten in: Biology open | 2023

von Schubert, L. | Le, A. | Hinz, T. | +5

UpdateOf: bioRxiv. 2023 Apr 06;:. - PMID 37066347

7

Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib

enthalten in: Chembiochem : a European journal of chemical biology | 2023

von Hu, Q. | Liao, Y. | Cao, J. | +8

8

A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes

enthalten in: bioRxiv.org | 2023

von Schubert, L. | Le, A. | Hinz, T. | +5

9

A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes

enthalten in: bioRxiv : the preprint server for biology | 2023

von Schubert, L. | Le, A. | Hinz, T. | +5

UpdateIn: Biol Open. 2023 Jul 20;:. - PMID 37470475

10

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Gounder, M. | Bauer, T. | Schwartz, G. | +12

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]